[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 53, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 842014, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.9, "open": 2.0, "dayLow": 1.6, "dayHigh": 2.0, "regularMarketPreviousClose": 1.9, "regularMarketOpen": 2.0, "regularMarketDayLow": 1.6, "regularMarketDayHigh": 2.0, "volume": 310601, "regularMarketVolume": 310601, "averageVolume": 101400, "averageVolume10days": 457100, "averageDailyVolume10Day": 457100, "bid": 1.58, "ask": 1.72, "bidSize": 200, "askSize": 100, "marketCap": 891791, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 441.714, "fiftyDayAverage": 4.25958, "twoHundredDayAverage": 42.43031, "currency": "USD", "enterpriseValue": -3462834, "floatShares": 283519, "sharesOutstanding": 543775, "sharesShort": 1286, "sharesShortPriorMonth": 1871, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0025, "heldPercentInsiders": 0.01702, "heldPercentInstitutions": 0.029849999, "shortRatio": 0.02, "shortPercentOfFloat": 0.0026, "bookValue": 11.379, "priceToBook": 0.14412515, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12774000, "trailingEps": -51.95, "enterpriseToEbitda": 0.288, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.64, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 4091000, "totalCashPerShare": 14.09, "ebitda": -12040000, "totalDebt": 152000, "quickRatio": 2.435, "currentRatio": 2.636, "debtToEquity": 5.432, "returnOnAssets": -2.79417, "freeCashflow": -6710500, "operatingCashflow": -10614000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-03"}]